Wall Street analysts expect Agile Therapeutics Inc (NASDAQ:AGRX) to announce ($0.13) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Agile Therapeutics’ earnings. Agile Therapeutics reported earnings per share of ($0.08) during the same quarter last year, which indicates a negative year-over-year growth rate of 62.5%. The company is scheduled to report its next earnings report after the market closes on Tuesday, August 11th.
According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.63) to ($0.55). For the next financial year, analysts expect that the firm will report earnings of ($0.33) per share, with EPS estimates ranging from ($0.62) to ($0.07). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01).
A number of large investors have recently made changes to their positions in AGRX. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Agile Therapeutics in the 1st quarter worth approximately $26,000. Jane Street Group LLC purchased a new stake in shares of Agile Therapeutics in the 4th quarter worth approximately $28,000. Comerica Bank purchased a new stake in shares of Agile Therapeutics in the 2nd quarter worth approximately $30,000. Perkins Capital Management Inc. purchased a new stake in shares of Agile Therapeutics in the 1st quarter worth approximately $40,000. Finally, Raymond James & Associates purchased a new stake in shares of Agile Therapeutics in the 4th quarter worth approximately $43,000. Institutional investors own 37.87% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Read More: Depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.